Researchers evaluated the effects of biologic and targeted synthetic DMARDs on patient-reported outcomes in rheumatoid arthritis.

DMARDs are a medication that suppresses the immune system. People may take them to slow disease progression in autoimmune or inflammatory conditions, such as different types of arthritis. Inflammation ...

rheumatoid arthritis dmard vs biologic Updated American College of Rheumatology recommendations suggest using first-line DMARDs in combination with biologic agents and nonbiologic DMARDs to achieve ...

Early diagnosis leads to earlier treatment. With earlier treatment of rheumatoid arthritis (RA), there is a better chance for less radiographic damage, less disability and thus lower overall costs of ...

Only slightly more than half of patients with newly diagnosed rheumatoid arthritis initiated therapy within 1 year. Objectives: To determine the rate of timely disease-modifying antirheumatic drug ...

In past decades, remission was seldom assessed as an outcome measure... An earlier randomized, placebo-controlled study of stoppage versus continuation of DMARD therapy in patients with longstanding ...

Please provide your email address to receive an email when new articles are posted on . Among patients with rheumatoid arthritis, observed rates of major adverse events from biologic/targeted ...

New disease-modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis are usually expensive and insurers, including Medicare, will often limit access. This study examined Medicare Advantage and ...